FOR IMMEDIATE RELEASE                    
                                                                                    Contact: Elise Bender 
(703) 766-1712
                                                                                          ebender@scct.org

CT-Guided Therapeutic Decision Making Enables a 
Reduction in Myocardial Infarction

SCCT Leadership Comments on New SCOT-HEART Substudy

Vienna, VA (April 25, 2016) - The results of a new study 1 , a secondary analysis of the SCOT-HEART (Scottish COmputed Tomography of the HEART) 2  trial, show that coronary computed tomography angiography (CCTA) leads to a more appropriate and effective selection of invasive coronary angiography for patients with suspected angina due to coronary heart disease. The use of CCTA also contributed to greater use of  preventive therapies that led to a 50% reduction in risk for fatal and non-fatal myocardial infarction when compared to usual care, largely including stress testing.

The SCOT-HEART trial demonstrated that CCTA markedly clarified the diagnosis for patients with suspected angina due to coronary heart disease. However, whether the CCTA-guided changes in diagnosis led to appropriate improvements in invasive coronary angiography and initiation of preventive treatments, and whether these changes could be attributable to an improvement in clinical outcome, had not been explored.
 
 "SCOT-HEART has shown for the first time that CT coronary angiography can be used to reduce mortality in patients with suspected coronary heart disease. We showed that computed tomography improved the certainty of diagnosis, changed the prescription of preventative therapies and led to more appropriate use of invasive coronary angiography," said lead author Michelle C. Williams, MD, MBChB, of the British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, UK. "This resulted in the halving of fatal and non-fatal myocardial infarction after these changes in management were implemented. With SCOT-HEART we have moved beyond studies of diagnostic accuracy, and this study will certainly change practice."

"With this seminal analysis, CCTA has moved from a diagnostic test with unparalleled accuracy and significant prognostic information, to a test that can effectively guide therapeutic decision making," said SCCT President Jonathon Leipsic, MD, FSCCT. "The ability to help guide treatment strategies that reduce hard events will inevitably disrupt traditional care pathways."

Commenting on this study, SCCT President-Elect Leslee Shaw, PhD, FSCCT noted that "new findings conclusively demonstrate that CCTA is by far one of the key components to guide accurate diagnosis of and effective treatment for coronary artery disease (CAD). These findings will provide a new approach to diagnosis and treatment of CAD. Although requiring future validation, this analysis suggests that optimal improvements in patient outcomes can best be facilitated by CCTA."

The potential implications of this study on patient management following CTA are profound, according to Todd Villines, MD, FSCCT, Chair of the SCCT Education Committee. He noted that "the identification of both non-obstructive and obstructive (potentially flow-limiting) coronary artery disease is a tremendous advantage of coronary CTA. These findings demonstrate that disease burden on CTA, including non-obstructive disease, leads to important therapeutic changes that significantly reduce a patient's risk of suffering a first heart attack."

In an accompanying editorial
3 , SCCT Past President Dr. James K. Min, FSCCT, Professor of Radiology at Weill Cornell Medical College and Director of the Dalio Institute of Cardiovascular Imaging at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, speaks to the implications of these results. "This secondary analysis of SCOT-HEART is the highest-quality evidence to date for the comparative benefit of CCTA over standard-of-care approaches...In aggregate, these studies suggest that not only may CCTA be considered a reasonable alternative to stress testing for initial diagnostic CAD evaluation, but it may actually be preferred."


1. Williams M, Hunter A, Shah A, Assi V, Lewis S, Smith J, Berry C, Boon N, Clark E, Flather M, Forbes J, McLean S, Roditi G, van Beek E, Timmis A, Newby, D. Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease. J Am Coll Cardiol. 2016; 67:1759-68
2. Newby D, Williams M, Hunter A, Pawade T, Shah A, et al. CT Coronary Angiography in Patients with Suspected Angina Due to Coronary Heart Disease (SCOT-HEART): An Open-label, Parallel-group, Multicentre trial. Lancet. 2015; 385(9985):2383-91
3. Min J, Jones E, Peña J. The Future From the Past: A Chance for Change. J Am Coll Cardiol. 2016; 67:1769-71
About the Society of Cardiovascular Computed Tomography  
SCCT is the professional society devoted exclusively to cardiovascular computed tomography. The Society is acknowledged and recognized as the representative and advocate for research, education and clinical excellence in the use of cardiovascular computed tomography. For more information on the society's mission and goals, please see the SCCT website at www.SCCT.org.

#             #                    
STAY CONNECTED WITH SCCT: